BioJapan exists to facilitate cooperation between Japanese and international biotech companies. At this year’s event in Yokohama, Domainex CEO Eddy Littler will be speaking to a gathering of the industry’s top scientific and business minds on the anti-inflammatory TBK1 & IKKε inhibitors developed by Domainex in a seminar titled ‘IKK epsilon inhibitors with activity in inflammatory disease: COPD, psoriasis and Lupus’.

http://www.ics-expo.jp/biojapan/